VIGAMOX^® Solution: Rapid Resolution of Bacterial Conjunctivitis

Acute Pediatric Conjunctivitis Is Predominantly Bacterial in Origin

Bacterial pathogens are implicated in 80% of conjunctivitis cases.

Click here to learn about common pathogens related to bacterial conjunctivitis

Bacterial Conjunctivitis Is Highly Contagious

The transmission of bacterial conjunctivitis is common in schools and day care centers, and may reach epidemic proportions.

Learn more about the highly contagious nature of bacterial conjunctivitis

VIGAMOX^® Solution Has a Rapid Speed of Bacterial Kill In Vitro

VIGAMOX^® solution demonstrated 99.9% eradication of Streptococcus pneumoniae and Haemophilus influenzae, in as little as an hour.^*†

Fluoroquinolones May Help to Achieve the Goals of Most State Health Departments to Minimize Transmission of Bacterial Conjunctivitis

Appropriate treatment intervention is required of most state health departments.

Learn how to prevent absenteeism and economic loss

*Patients should be instructed to use the full course of therapy — 7 days.
†In vitro data are not always indicative of clinical success or microbiological eradication in a clinical setting. Clinical significance unknown.

VIGAMOX^® solution Important Safety Information

VIGAMOX^® solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species*, Micrococcus luteus*, Staphylococcus aureus, S. epidermidis, S. haemolyticus, S. hominis, S. warneri*, Streptococcus pneumoniae, Streptococcus viridans group, Acinetobacter lwoffii*, Haemophilus influenzae, Haemophilus parainfluenzae*, Chlamydia trachomatis (*efficacy for this organism was studied in fewer than 10 infections). VIGAMOX^® solution is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other fluoroquinolones, or to any of the components in this medication. NOT FOR INJECTION. VIGAMOX^® solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye. In patients receiving systemically administered quinolones, including moxifloxacin, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, some following the first dose. As with other anti-infectives, prolonged use of VIGAMOX^® solution may result in overgrowth of non-susceptible organisms, including fungi. The safety and effectiveness of VIGAMOX^® solution in infants below 1 year of age have not been established. The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. These events occurred in approximately 1%–6% of patients. The dosing of VIGAMOX^® solution is one drop in the affected eye(s) 3 times daily for 7 days.

Please click here for full Prescribing Information.

Licensed to Alcon, Inc. by Bayer HealthCare AG

VIGAMOX® Solution: Rapid Resolution of Bacterial Conjunctivitis